Pre- and postvaccination SBA titers
| . | Denominator . | N . | % . | 95% CI . |
|---|---|---|---|---|
| Prevaccination SBA titers ≥1:8 | ||||
| Serogroup A | 67 | 15 | 22.4 | 14.1-33.7 |
| Serogroup C | 67 | 12 | 17.9 | 10.6-28.7 |
| Serogroup W-135 | 67 | 9 | 13.4 | 7.2-23.6 |
| Serogroup Y | 67 | 7 | 10.4 | 5.1-20.0 |
| Postvaccination SBA titers ≥1:8 | ||||
| Serogroup A | 67 | 54 | 80.6 | 69.6-88.3 |
| Serogroup C | 67 | 44 | 65.7 | 53.7-75.9 |
| Serogroup W-135 | 67 | 38 | 56.7 | 44.8-67.9 |
| Serogroup Y | 67 | 44 | 65.7 | 53.7-75.9 |
| Polyvalent vaccine SBA titers ≥1:8 | ||||
| 4 Serogroups | 67 | 29 | 43.3 | 32.1-55.2 |
| 3 Serogroups | 67 | 11 | 16.4 | 9.4-27.1 |
| 2 Serogroups | 67 | 11 | 16.4 | 9.4-27.1 |
| 1 Serogroup | 67 | 9 | 13.4 | 7.2-23.6 |
| 0 Serogroup | 67 | 7 | 10.4 | 5.1-20.0 |
| Postvaccination SBA titers ≥1:8 in nonimmune patients at baseline | ||||
| Serogroup A | 52 | 40 | 76.9 | 63.9-86.3 |
| Serogroup C | 55 | 36 | 65.5 | 52.3-76.6 |
| Serogroup W-135 | 58 | 30 | 51.7 | 39.2-64.1 |
| Serogroup Y | 60 | 39 | 65.0 | 53.4-75.8 |
| Postvaccination SBA titers ≥1:8 in immune patients at baseline | ||||
| Serogroup A | 15 | 14 | 93.3 | 70.2-98.8 |
| Serogroup C | 12 | 8 | 66.7 | 39.1-86.2 |
| Serogroup W-135 | 9 | 8 | 88.9 | 56.5-98.0 |
| Serogroup Y | 7 | 5 | 71.4 | 35.9-91.8 |
| Postvaccination median SBA titers | ||||
| Serogroup A (IQR) | 67 | 1:2048 | (1:256-1:8192) | |
| Serogroup C (IQR) | 67 | 1:64 | (1:4-1:512) | |
| Serogroup W-135 (IQR) | 67 | 1:128 | (1:2-1:2048) | |
| Serogroup Y (IQR) | 67 | 1:128 | (1:2-1:1024) | |
| . | Denominator . | N . | % . | 95% CI . |
|---|---|---|---|---|
| Prevaccination SBA titers ≥1:8 | ||||
| Serogroup A | 67 | 15 | 22.4 | 14.1-33.7 |
| Serogroup C | 67 | 12 | 17.9 | 10.6-28.7 |
| Serogroup W-135 | 67 | 9 | 13.4 | 7.2-23.6 |
| Serogroup Y | 67 | 7 | 10.4 | 5.1-20.0 |
| Postvaccination SBA titers ≥1:8 | ||||
| Serogroup A | 67 | 54 | 80.6 | 69.6-88.3 |
| Serogroup C | 67 | 44 | 65.7 | 53.7-75.9 |
| Serogroup W-135 | 67 | 38 | 56.7 | 44.8-67.9 |
| Serogroup Y | 67 | 44 | 65.7 | 53.7-75.9 |
| Polyvalent vaccine SBA titers ≥1:8 | ||||
| 4 Serogroups | 67 | 29 | 43.3 | 32.1-55.2 |
| 3 Serogroups | 67 | 11 | 16.4 | 9.4-27.1 |
| 2 Serogroups | 67 | 11 | 16.4 | 9.4-27.1 |
| 1 Serogroup | 67 | 9 | 13.4 | 7.2-23.6 |
| 0 Serogroup | 67 | 7 | 10.4 | 5.1-20.0 |
| Postvaccination SBA titers ≥1:8 in nonimmune patients at baseline | ||||
| Serogroup A | 52 | 40 | 76.9 | 63.9-86.3 |
| Serogroup C | 55 | 36 | 65.5 | 52.3-76.6 |
| Serogroup W-135 | 58 | 30 | 51.7 | 39.2-64.1 |
| Serogroup Y | 60 | 39 | 65.0 | 53.4-75.8 |
| Postvaccination SBA titers ≥1:8 in immune patients at baseline | ||||
| Serogroup A | 15 | 14 | 93.3 | 70.2-98.8 |
| Serogroup C | 12 | 8 | 66.7 | 39.1-86.2 |
| Serogroup W-135 | 9 | 8 | 88.9 | 56.5-98.0 |
| Serogroup Y | 7 | 5 | 71.4 | 35.9-91.8 |
| Postvaccination median SBA titers | ||||
| Serogroup A (IQR) | 67 | 1:2048 | (1:256-1:8192) | |
| Serogroup C (IQR) | 67 | 1:64 | (1:4-1:512) | |
| Serogroup W-135 (IQR) | 67 | 1:128 | (1:2-1:2048) | |
| Serogroup Y (IQR) | 67 | 1:128 | (1:2-1:1024) | |
CI, confidence interval.